Tenon Medical (TNON) EBITDA (2021 - 2026)

Tenon Medical has reported EBITDA for 6 years, with the latest figure at -$3.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 9.29% year-over-year to -$3.3 million; the trailing twelve-month figure through Mar 2026 stood at -$12.2 million (up 10.89% YoY), and the FY2025 full-year result was -$12.6 million, up 7.86% from the prior year.
• EBITDA for Q1 2026 stood at -$3.3 million, down from -$2.8 million in the prior quarter.
• The five-year high for EBITDA was -$2.4 million in Q1 2022, with the low at -$7.8 million in Q4 2022.
• Average EBITDA over 5 years is -$3.8 million, with a median of -$3.3 million recorded in 2025.
• Year-over-year, EBITDA sank 1076.5% in 2022 and surged 60.72% in 2023.
• Tracing TNON's EBITDA over 5 years: stood at -$7.8 million in 2022, then surged by 60.72% to -$3.1 million in 2023, then slipped by 0.29% to -$3.1 million in 2024, then advanced by 8.26% to -$2.8 million in 2025, then decreased by 15.82% to -$3.3 million in 2026.
• The last three EBITDA figures came in at -$3.3 million (Q1 2026), -$2.8 million (Q4 2025), and -$3.3 million (Q3 2025), per Business Quant data.

Peer Comparison